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Available online 10 May 2011Abstract The osteogenic differentiation of progenitor populations allows analysis of cell functionality as well as creating a
platform for investigating stem cells for bone tissue engineering. Protocols used for osteogenic differentiation of progenitor cells
are often identical to those detailed for bonemarrowmesenchymal stem cells, however this may be flawed due to cell populations
residing in different niches and being in distinct stages of differentiation.Weherein describe the individual and combined effects of
known osteo-inductive agents; dexamethasone (Dex), 1,25-dihydroxyvitamin D3 (VitD3), all trans-retinoic acid (atRA), cyclic AMP
(cAMP) and bone morphogenic protein 2 (BMP2) in combination with fetal bovine serum (FBS) on osteogenesis of human periosteal
derived cells (hPDCs). The addition of Dex&FBS was essential for the transition of hPDCs to an ALP positive cell population.
Subsequently, atRA, Dex&FBS and BMP2were required for the expression of transcription factors governing osteogenesis and hence
differentiation towards a mature osteoblast. It is also hypothesized that Dex has no direct effect on the differentiation of hPDCs,
instead its effect is to augment differentiation in combination with other factors. These data provide a comprehensive assessment
of known osteogenic factors, in a novel multiplex system, to evaluate their effect on progenitor cell differentiation.
© 2011 Elsevier B.V. All rights reserved.Introduction
The in vitro differentiation of progenitor cells allows re-
searchers to manipulate cellular environment, signaling and
interactions without the interference of other cell/tissue
types. These differentiation models are not only useful for
increasing the understanding of stem cell kinetics but are also
applicable to tissue engineering as a system to investigate⁎ Corresponding author at: Laboratory for Skeletal Development
and Joint Disorders, Onderwijs en Navorsing 8th floor, bus 813;
B-3000, Leuven, Belgium. Fax: +32 16 34 25 43.
E-mail address: Frank.Luyten@uz.kuleuven.be (F.P. Luyten).
1873-5061/$ - see front matter © 2011 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2011.04.003tissue formation in vitro. It has also been previously
documented that the treatment of progenitor cells with
factors which enhance differentiation in vitro can have a
positive effect on tissue formation in vivo (Siddappa et al.,
2008; Song et al., 2009). Thus, to allow the use of stem cells as
a cell source for clinical applications, establishment of defined
differentiation conditions for specific stem cell populations is
of utmost importance.
When considering osteogenic differentiation most work
has been carried out on bone marrow mesenchymal stem
cells (BM-MSCs). The current gold standard for osteogenic
differentiation of this cell type is regarded as basal medium.
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(Dex), β-glycerophosphate (β-GP) and L-ascorbic acid-2-
phosphate (AsAP) (Jaiswal et al., 1997). This formulation has
been shown to exhibit a robust differentiation for BM-MSCs,
however some caveats exist for alternative cell populations.
For example, Dex causes a dual differentiation of adipose
derived cells to both adipocytes and osteoblasts under
osteogenic conditions (Arutyunyan et al., 2009). This has
been attributed to Dex potentially augmenting differentia-
tion of MSCs and not specifically directing differentiation
(Oshina et al., 2007). This effect is unsurprising considering
most progenitor cells are developmentally in various stages
of differentiation and residing within different niches.
Alternative osteogenic stimulators have been described
including 1,25-dihydroxyvitamin D3 (VitD3) (Liu et al., 1999),
all trans-retinoic acid (atRA) (Wan et al., 2006), cyclic AMP
(cAMP) (Siddappa et al., 2008) and bonemorphogenic protein 2
(BMP2) (Rickard et al., 1994), however confounding results on
osteogenic differentiation have also been documented with
many of these. For example Dex has been shown to block
osteogenic differentiation of murine osteoprogenitor cells
with VitD3 shown to down regulate osteocalcin (OCN) within
the same cell type (Lian et al., 1997). Additionally, FBS within
cell culture media can also have a negative effect on
differentiation due to endogenous growth factors interfering
with cellular processes such as BMP signaling (Zilberberg et al.,
2007).
A major limitation in studies aiming to elucidate differen-
tiation conditions is the absence of investigating interactions
between inductive agents. This limitation is perhaps due to the
absence of quantitative experimental designs for the assess-
ment of multiple factors in a multiplex assay, which can be
used to define factors and interactions to promote cellular
differentiation. We herein provide a novel methodology to
elucidate effects of known osteogenic factors on the differ-
entiation of human periosteal derived cells (hPDCs). These areTable 1 Experimental setup (resolution IV and two-level fractiona
stimulants in each differentiation condition. Dex, atRA, VitD3, cAMP,
ascorbic acid 2-phosphate (AsAP) and 10 mM β-glycerophosphate (β-G
16 different differentiation conditions (1 to 16).
Condition Pattern Dex (nM) atRA (μM) V
1 −−−−−− 0 0
2 −++−−− 0 5 1
3 ++−+−− 100 5
4 +−++−− 100 0 1
5 +−−−+− 100 0
6 +++−+− 100 5 1
7 −+−++− 0 5
8 −−+++− 0 0 1
9 ++−−−+ 100 5
10 +−+−−+ 100 0 1
11 −−−+−+ 0 0
12 −+++−+ 0 5 1
13 −+−−++ 0 5
14 −−+−++ 0 0 1
15 +−−+++ 100 0
16 ++++++ 100 5 1progenitor cells which are known to be involved in bone
development and postnatal repair processes and are therefore
a promising starting population for clinically relevant skeletal
tissue engineering (Roberts et al., 2011). The analysis of
differentiation achieved through a factorial design strategy
which allows the direct contribution of each factor to
measurable outcomes to be evaluated along with potential
interactions thereof. This work represents a first step to
elucidate specific factors which can enhance the osteogenic
differentiation of hPDCs. Additionally, it provides a novel
strategy for the investigation of stem cell differentiation for
the development of cell-customized in vitro conditions as part
of a tissue engineering approach.Results
Morphological changes in hPDC cultures
To investigate the effect of Dex, VitD3, atRA, BMP2, cAMP
and FBS on osteogenic differentiation of hPDCs, a factorial
design was employed utilizing high and low concentrations of
each factor. Sixteen different compositions of media were
formulated (Table 1) and used to grow cells for a period of
14 days. Note that differentiating condition 1 (Con-1)
contains basal low levels of all factors and condition 16
(Con-16) contains high levels of all factors. Upon analysis of
cultures differences were observed in cell morphology, as
shown in Fig. 1. Media containing 1% FBS resulted in visibly
less cells (Fig. 1, panels 1–8), however cell morphology
varied from fibroblastic-like (Fig. 1, panels 1, 2, 6, 7, 8) to
cuboidal-like cells (Fig. 1, panels 3, 4, 5; white arrows). High
FBS containing media resulted in visibly more cells (Fig. 1,
panels 9–16), also with variable morphology including nodule
like structures (Fig. 1, panels 10, 14, 15; white stars) and also
cuboidal cells (Fig. 1, panel 11; white arrows), indicating al factorial design (26− 2 design)) showing patterns of osteogenic
BMP2 and FBS were added to basal media containing 50 μg/ml
P), in the concentration and the pattern indicated, to produce
itD3 (nM) cAMP (μM) BMP2 (ng/ml) FBS (%)
0 0 0 1
00 0 0 1
0 500 0 1
00 500 0 1
0 0 50 1
00 0 50 1
0 500 50 1
00 500 50 1
0 0 0 10
00 0 0 10
0 500 0 10
00 500 0 10
0 0 50 10
00 0 50 10
0 500 50 10
00 500 50 10
Figure 1 Cell morphology of hPDCs undergoing osteogenic differentiation. hPDCs were cultured and differentiated using each of the
differentiation conditions as outlined in Table 1 using the techniques described in Materials and methods. Following 14 days
microscopic images depicting cellular morphology were taken. Note the presence of cuboidal cells (white arrows) and nodular-like
structures (white stars) in certain conditions. (Scale bar: 200 μm).
139Osteogenic differentiation of hPDCsrange and extent of differentiation when comparing each of
the 16 conditions.
Analysis of proliferation/differentiation
Analysis of cell number from each culture confirmed the
observations described above. Cultures 1 to 8 (1% FBS)
contained between 1.1×104±1213 cells/cm2 and 1.8×104±
1234 cells/cm2 which, when compared to the condition
containing the highest cell number (condition 10), was
approximately 10 fold lower (Fig. 2I). The high FBS
concentration (10%) allowed greater cell proliferation
which allowed for cell numbers between 2.9 × 104 ±
1061 cells/cm2 and 12.5×104 ±9145 cells/cm2. Alkaline
phosphatase (ALP) activity was highest in culture 10 (121.2±
12.3 R.U./μg DNA) and lowest in condition 13 (5.6±
0.7 R.U./μg DNA) (Fig. 2II). Gene expression for transcrip-
tional co-activator with PDZ-binding motif (TAZ) revealed
higher expression in cultures 1 to 8 when compared to 9 to
16 (Fig. 2III). Runx2 expression was variable throughout the
16 culture conditions (Fig. 2IV). Osterix expression peaked in
conditions 7, 8 and 13 (Fig. 2V) and OCN expression was
high in conditions 2, 8 and 14 (Fig. 2VI).
Contribution of specific factors to osteogenic
differentiation
As each of the 16 culture conditions was designed using
factorial analysis, the specific contribution of each factor,
and potential interactions thereof, could be assessed for
significance to each measured output. When considering
the ‘main effects’ from each of the factors it was clear that
FBS had the largest positive effect on cell proliferation,
conversely atRA had the largest negative effect (Fig. 3I).When considering ALP activity atRA had the largest negative
effect; with the largest positive effect for ALP coming from
cAMP. However potential interactions were considered, the
largest overall positive effect for ALP activity came from the
interaction of Dex with FBS (Fig. 3II). TAZ expression was
mainly stimulated with atRA, with a potential positive
interaction with cAMP, and repressed by FBS (Fig. 3III). Dex
and BMP2 had the largest negative effect on Runx2
expression. Only FBS had a significant positive effect on
the expression of this gene. Interestingly, when factor
interactions were considered Dex had a possible positive
effect on Runx2 expression when combined with atRA and/or
FBS (Fig. 3IV). BMP2 had the largest positive influence on the
expression of Osterix with Dex&FBS having the largest
negative effect (Fig. 3V). VitD3 exhibited the greatest
positive influence on OCN expression with Dex contributing
predominantly to the repression of this gene (Fig. 3VI).
Discussion
Osteogenic differentiation, as observed during intramem-
branous ossification, involves the following processes:
(1) cell proliferation (2) cell migration–aggregation and
(3) cell differentiation with the dynamic expression of
osteogenic transcription and growth factors (Karner et al.,
2009). To replicate this differentiation profile, culture
conditions which will allow promotion of these key events
would be required. Early osteogenic differentiation is
characterized firstly by a proliferative burst, including the
formation of nodule-like structures, accompanied by the
expression of ALP. ALP induction is a key event in the
differentiation of osteoblasts as it mediates matrix mineral-
ization and hence bone tissue formation. It is also one of the
earliest markers of osteoblastic differentiation.
Figure 2 Analysis of hPDC proliferation and osteogenic differentiation. hPDCs were cultured and differentiated using the 16
differentiation conditions outlined in Table 1. Following 14 days DNA was extracted, ALP activity (R.U.=absorbance at 620 nm)
monitored and osteogenic gene expression quantified described in Materials and methods. (I) Cell number, (II) ALP activity, (III) TAZ
expression, (IV) Runx2 expression, (V) Osterix expression and (VI) Osteocalcin (OCN) expression. Statistical significance is compared to
the mean of the data (horizontal dashed line). *: pb0.05, **: pb0.01, ***: pb0.001.
140 S.J. Roberts et al.Proliferation of hPDCs was positively influenced by FBS and
to a lesser extent VitD3. Interestingly, nodule-like structures
(Fig. 1) were only observed in FBS-containing media indicating
the requirement of proliferation for this effect. atRA has the
greatest negative effect on both cellular proliferation and ALP
induction,which has been reported previouslywith alternative
cell types including vascular smooth muscle cells (Kosaka
et al., 2001) and osteoblast-like cells respectively (Kaji et al.,
1995; Ogston et al., 2002). Conversely, atRA has also been
reported to have a stimulatory effect (James et al., 2010) on
ALP activity suggesting cellular specificity when considering
this factor. The addition of cAMP to cultures has the greatest,
single factor, stimulatory effect on ALP induction, which has
previously been documented with human MSCs. Addition of
cAMP to MSC cultures has also previously been shown toimprove in vivo bone formation (Siddappa et al., 2008).
Additionally, the interaction of Dex and FBS (Dex&FBS) has the
largest overall positive effect on ALP induction. Indeed it has
been previously documented that an ALP-negative cell
population could form bone nodules in vitro only after Dex
treatment, whereas ALP-positive populations could form
nodules in vitro without Dex (Turksen and Aubin, 1991).
VitD3 also had a stimulatory effect on ALP activity within
hPDCs, which has been previously reported (Uchida et al.,
1988), however this was less than that observed with Dex&FBS
and cAMP. Consequently, it is clear that Dex&FBS and cAMP are
required to facilitate the differentiation of hPDCs to early
osteoprogenitors which display positivity for ALP.
To further elucidate factors which allow differentiation to
specific stages of maturation, key transcription factors which
Figure 3 Plots of the standardized effects for each factor. Normal probability plots of main (one) factor effects and potential two-
factor interactions for (I) DNA content, (II) ALP activity, (III) TAZ expression, (IV) Runx2 expression, (V) Osterix expression and (VI) OCN
expression. Each factor is defined by the following single letter code (D) Dex, (R) atRA, (V) VitD3, (C) cAMP, (B) BMP2, (F) FBS.
Statistically significant factors (pb0.05) are indicated in gray while black points indicate non-significant factors. The diagonal line
transecting each plot indicates perfect non-significance, thus increasing departure from this line implies increasing significance.
141Osteogenic differentiation of hPDCsgovern differentiation of MSCs to osteoblasts were investi-
gated. TAZ expression has been previously hypothesized to
indicate the degree of differentiation of MSCs towards the
osteoblastic lineage. TAZ acts downstream of Runx2 and
assists in secretion of bone matrix-related proteins (Hong
et al., 2005). Runx2 is involved in osteoblast differentiation
and bone formation. In particular, Runx2 is required for early
commitment of MSCs to osteoprogenitors, and also functions
later in osteoblast differentiation to regulate the formation
of the extracellular matrix (Ducy et al., 1999). Osterix is a
zinc finger-containing transcription factor that is specifically
expressed in osteoblasts of all skeletal elements and acts
downstream of BMP2/p38 signaling (Ulsamer et al., 2008).atRA has the greatest positive effect on TAZ transcription
with FBS having the greatest negative effect, indicating that
cellular proliferation is inhibitory to the expression of this
transcription factor. It has previously been suggested that
atRA may play an important role in the expression of this
gene (Wan et al., 2006), however, this has previously not
been experimentally defined. Furthermore, FBS stimulated
the production of Runx2 while Dex inhibited it. However,
the indicated potential interactions with Dex which have a
positive effect on Runx2 expression further highlights the
complexities of in vitro osteogenic differentiation. When
considering the expression of Osterix again Dex has an
inhibitory effect with the greatest positive effect being
142 S.J. Roberts et al.attributed to BMP2. This interaction has previously been
described and indeed has been shown to exist in a Runx2
independent fashion (Lee et al., 2003). Interestingly, FBS has
a negative effect on Osterix expression which may be due to
reduced BMP signaling as Osterix lies downstream from BMP/
p38 and FBS has previously been shown to have a detrimental
effect on this pathway (Zilberberg et al., 2007). These data
suggest that expression of the key regulators of osteogenic
differentiationwithin hPDCs is reliant on the activation of Dex,
atRA and BMP mediated signaling pathways. Additionally,
BMP2 has a dual function within the final stages
of differentiation by inducing Osterix while simultaneously
repressing Runx2, as observed developmentally (Komori,
2008). This gives rise to the hypothesis that the sequential
addition of these factors may potentially nurture hPDCs
through osteoblastic differentiation as observed during intra-
membranous ossification (a schematic representation of
this is shown in Supplementary Fig. 1). Interestingly, synergy
between these key regulators of osteoblastogenesis has been
previously documented, albeit in established cell lines
(Benayahu et al., 1994).
OCN is a marker of late stage osteogenic differentiation
and regulates matrix mineralization during bone formation.
VitD3 had the greatest positive effect on this transcript while
Dex had the greatest negative effect. This effect has
previously been documented for VitD3 supplemented oste-
oblast cultures (Viereck et al., 2002), however not for hPDCs.
Interestingly, Dex again has a negative effect on the
expression of this gene indicating that perhaps the role of
Dex is in early augmentation of differentiation and the effect
on late differentiation is negative. This hypothesis is
substantiated through reports that Dex can attenuate VitD3
induced OCN expression (Schepmoes et al., 1991). Indeed it
has been reported that the main effect of Dex on osteoblasts
is through the modulation of cell cycle regulatory elements
such as increased p27kip1 and decreased p21waf1/cip1
levels. The attenuation of osteoblast growth to high density
by Dex is associated with severe impairment of mineralized
extracellular matrix formation (Smith et al., 2000), however
this may also be related to the timing cellular stimulation
with Dex (McCulloch and Tenenbaum, 1986). Additionally,
althoughVitD3has the largest positive effect onOCNexpression
a smaller, but significant, positive effect is observed with the
interaction of Dex&FBS. This may be due to the positive effect
of the Dex&FBS interaction on Runx2 expression as OCN is a
direct target of this transcription factor (Frendo et al., 1998).
In conclusion, we have herein demonstrated a novel
methodology for the investigation and customization of stem
cell differentiation using multiple factor analysis. From this it
is clear that addition of FBS and Dex are essential for the
transition of hPDCs to an ALP positive cell population.
Subsequently, atRA, Dex&FBS and BMP2 are required to
allow expression of the main transcription factors governing
osteogenesis and hence differentiation towards a mature
osteoblast. Although we propose these factors as key
regulators in osteogenic differentiation of hPDCs, further
work is required to elucidate the precise mechanism by which
their influence is exerted. This is highlightedwhen considering
the negative or no effect of certain factors individually, which
is changed to a positive effect when combined with other
factors in a proposed interaction. This is hypothesized to be
due to multiple signaling pathways being affected simulta-neously and emphasizes the complexity of stem cell differen-
tiation. We also propose that the use of specific factors may
alter the rate of osteogenic differentiation, as despite using a
single time point, a range of early and late markers were
apparentwithin each of the conditions. This study provides the
first insight on how to optimize differentiation conditions with
respect to specific progenitor cell types. Thiswill allow further
study on osteogenic differentiation of hPDCs for bone tissue
engineering.
Materials and methods
Harvest of periosteal tissue and isolation of the cells
Periosteal biopsies (0.5 cm²) were harvested from the
medial side of the proximal tibia of male and female
adolescent and adult patients during total knee replacement
surgery or distraction osteogenesis. The periosteum was
stripped from the tibia with a periosteal lifter. The
periosteal specimens were transported in growth medium
consisting of high-glucose Dulbecco's Modified medium
(DMEM, Invitrogen, Merelbeke, Belgium) supplemented
with 10% FBS (BioWhittaker, Verviers, Belgium) and antibi-
otic–antimycotic solution (100 units/ml penicillin, 100 μg/ml
streptomycin, and 0.25 μg/ml amphotericin B; Invitrogen,
Merelbeke, Belgium). The biopsies were finely minced and
digested overnight at 37 °C in 0.2% type IV collagenase
(Invitrogen, Merelbeke, Belgium) in growth medium (as
described above). Subsequently periosteal cells were
collected by centrifugation and seeded in a T25 flask in
growth medium. Non-adherent cells were removed after
5 days by changing the medium. A pool of hPDCs was
subsequently created [n=6, age 14.9 (SD±2.1)] to reduce
noise from genetic variability. The ethical committee for
Human Medical Research (Katholieke Universiteit Leuven)
approved all procedures, and patient informed consent
forms were obtained.
Cell culture
Cells were expanded in monolayer in growth medium. Upon
confluence, hPDCs were trypsin released (0.25% trypsin, 1 mM
EDTA; Invitrogen, Merilee, Belgium) and re-plated with a
seeding density of 7500 cells/cm². For cryopreservation, hPDCs
were suspended in DMEM with 20% FBS and 10% DMSO (Sigma,
Borne, Belgium) and stored in liquid nitrogen. For the in vitro
osteogenic differentiation cells were thawed, re-plated and
expanded in 12 well plates at a density of 10,000 cells/cm² in
growth media containing 50 μg/ml AsAP and 10 mM β-GP.
Factorial design and osteogenic stimulation
A resolution IV and two-level fractional factorial design (26−2
design) in triplicate was implemented as experimental design
in this study. There were six factors used for this design: Dex,
VitD3, atRA, BMP2, cAMP and FBS, resulting in sixteen runs for
every medium formulation. Each factor was investigated at a
high (+1) and a low (−1) level (design and concentration is
indicated in Table 1). Resolution IV means that no main effect
is aliased with any other main effect or with any two-factor
143Osteogenic differentiation of hPDCsinteraction, but two-factor interactions are aliased with each
other (Box et al., 1978). The experimental data collected from
the implemented fractional factorial design was processed by
the Minitab 14 statistics package to obtain relative contribu-
tion of each factor to the final effect.
Osteogenic stimulants and respective concentrations were
selected following a thorough review of literature on osteo-
genic differentiation of progenitor cells. Sixteen different
combinations of osteogenic stimulants were created with
alternative high and low levels of each factor as shown in
Table 1. All factors were purchased from Sigma. Cells were
seeded at 7500 cells/cm² and following 48 h culture the
different media formulations were added randomly, in tripli-
cate, to individual wells of 12 well plates. The media was
changed every 3 days and cells harvested on day 14 for ALP,
DNA and RNA analysis.
Biochemical and molecular analysis
Cell cultures were harvested and lysed in 0.05% Triton-X100
(in PBS). The DNA content was quantified using Quant-iT™
dsDNAHS Assay Kit (Invitrogen). The concentration of DNAwas
converted to a predicted cell number using a pre-determined
value of 6.93 pg DNA/hPDC. The ALP levels were measured
using BluePhos® Microwell Phosphatase Substrate System at
620 nm (Kirkegaard & Perry Laboratories). The ALP activity
was calculated by normalizing the absorbance of each sample
to the DNA content of each well (R.U.=absorbance at
620 nm).
Total RNA of each samplewas isolated by using Nucleospin®
RNA extraction kit (Macherey-Nagel) and quantified by using
Nanodrop ND-1000 spectrophotometer (Thermo Scientific).
Complementary DNA (cDNA) was synthesized by reverse
transcription of 250 ng of total RNA using RevertAid™ H Minus
First Strand cDNA synthesis kit with Oligo(dT)18 as primer
(Fermentas). SYBR green qPCR primers were designed to span
an intron so only RNA specific amplification was possible. The
PCR reaction was cycled in a Rotor-Gene sequence detector as
follows: 95 °C for 3 min, 40 cycles of 95 °C for 3 s and 60 °C for
60 s. Each sample was tested in duplicate and compared with
β-actin expression as described previously (Chai et al., 2011).
Relative differences in expression were calculated using the
2−ΔCT method (Schmittgen and Livak, 2008).
Statistical analysis
Data are expressed as mean±SD. Statistical significance was
determined using ANOVA with Minitab 14. Statistical signif-
icance is indicated as follows: *: pb0.05, **: pb0.01, and
***: pb0.001.
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